ATE157990T1 - Monoklonale antikörper gegen den humanen alpha/beta-t-zellenrezeptor, ihre herstellung und verwendung - Google Patents

Monoklonale antikörper gegen den humanen alpha/beta-t-zellenrezeptor, ihre herstellung und verwendung

Info

Publication number
ATE157990T1
ATE157990T1 AT90306178T AT90306178T ATE157990T1 AT E157990 T1 ATE157990 T1 AT E157990T1 AT 90306178 T AT90306178 T AT 90306178T AT 90306178 T AT90306178 T AT 90306178T AT E157990 T1 ATE157990 T1 AT E157990T1
Authority
AT
Austria
Prior art keywords
beta
monoclonal antibodies
cell receptor
antibodies against
human alpha
Prior art date
Application number
AT90306178T
Other languages
English (en)
Inventor
Roland Kurrle
Clyde W Shearman
Gordon P Moore
Fritz Seiler
Original Assignee
Genzyme Corp
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp, Behringwerke Ag filed Critical Genzyme Corp
Application granted granted Critical
Publication of ATE157990T1 publication Critical patent/ATE157990T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
AT90306178T 1989-06-07 1990-06-07 Monoklonale antikörper gegen den humanen alpha/beta-t-zellenrezeptor, ihre herstellung und verwendung ATE157990T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36254989A 1989-06-07 1989-06-07
US52997990A 1990-05-25 1990-05-25

Publications (1)

Publication Number Publication Date
ATE157990T1 true ATE157990T1 (de) 1997-09-15

Family

ID=27001722

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90306178T ATE157990T1 (de) 1989-06-07 1990-06-07 Monoklonale antikörper gegen den humanen alpha/beta-t-zellenrezeptor, ihre herstellung und verwendung

Country Status (8)

Country Link
EP (1) EP0403156B1 (de)
JP (1) JPH03219896A (de)
AT (1) ATE157990T1 (de)
CA (1) CA2018248A1 (de)
DE (1) DE69031410T2 (de)
DK (1) DK0403156T3 (de)
ES (1) ES2109228T3 (de)
GR (1) GR3025644T3 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5994510A (en) * 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
FR2672901B1 (fr) * 1991-02-15 1994-09-30 Immunotech Sa Nouvelles molecules de dna recombinants codant pour une chaine du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant.
DE4109884A1 (de) * 1991-03-26 1992-10-01 Claas Ohg Steuerung einer verdraengermaschine eines hydrostatisch-mechanischen lastschaltgetriebes
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
GB9325182D0 (en) * 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
AU705010B2 (en) * 1994-11-16 1999-05-13 Arizona Board Of Regents On Behalf Of The University Of Arizona, The Human antibodies to t-cell receptor peptides and methods for their preparation
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
CA2735193A1 (en) * 2008-08-26 2010-03-11 Macrogenics, Inc. T-cell receptor antibodies and methods of use thereof
UY34317A (es) * 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
BR112014010532A2 (pt) * 2011-11-03 2017-04-18 Tolera Therapeutics Inc anticorpo e métodos para inibição seletiva de respostas de célula-t
US20130273089A1 (en) 2011-11-03 2013-10-17 Tolera Therapeutics, Inc. Antibody and methods for selective inhibition of t-cell responses
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
BR112015020885A2 (pt) 2013-03-11 2017-10-10 Genzyme Corp polipeptídeos de ligação hiperglicosilados
EP3063174B1 (de) 2013-10-30 2020-12-09 Genzyme Corporation Verfahren zur verbesserung einer immunsuppressiven therapie durch mehrfache verabreichung von alpha-beta-tcr-bindendem polypeptid
EP3129067B1 (de) 2014-03-19 2023-01-04 Genzyme Corporation Ortsspezifisches glycoengineering von targeting-teilen
EP3148580B1 (de) 2014-05-29 2021-01-20 MacroGenics, Inc. Trispezifische bindungsmoleküle mit spezifischer bindung an mehrere krebsantigene und verfahren zur verwendung davon
CA2964123C (en) 2014-10-09 2023-09-05 Genzyme Corporation Glycoengineered antibody drug conjugates
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
CN107109369B (zh) * 2014-11-20 2021-07-09 Umc乌德勒支控股有限公司 用于富集具有外源性免疫受体的工程化t细胞的抗体的用途和用于清除工程化t细胞的抗体
RS63574B1 (sr) * 2015-02-06 2022-10-31 Nat Univ Singapore Metode za povećanje efikasnosti imuno ćelija
SG11201804839WA (en) 2015-12-14 2018-07-30 Macrogenics Inc Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
WO2017142928A1 (en) 2016-02-17 2017-08-24 Macrogenics, Inc. Ror1-binding molecules, and methods of use thereof
SG11201808979UA (en) 2016-04-15 2018-11-29 Macrogenics Inc Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
SG11201810883TA (en) 2016-06-07 2019-01-30 Macrogenics Inc Combination therapy
CN109997041B (zh) 2016-06-10 2022-10-28 歌德塔有限公司 人白细胞抗原限制的γδT细胞受体及其使用方法
US10550183B2 (en) 2016-11-22 2020-02-04 National University Of Singapore Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
HRP20211744T1 (hr) 2017-07-14 2022-02-04 Immatics Biotechnologies Gmbh Poboljšana molekula polipeptida dvostruke specifičnosti
AU2018313939A1 (en) 2017-08-10 2020-02-06 National University Of Singapore T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof
EP3818083A2 (de) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr-antikörpermoleküle und ihre verwendungen
GB201817172D0 (en) 2018-10-22 2018-12-05 Autolus Ltd Antibody
AU2020253455A1 (en) 2019-04-03 2021-11-04 Genzyme Corporation Anti-alpha beta TCR binding polypeptides with reduced fragmentation
EP3946382A1 (de) 2019-04-04 2022-02-09 UMC Utrecht Holding B.V. Modifizierte immunrezeptorkonstrukte
CN114729305A (zh) * 2019-10-17 2022-07-08 苏州丹罗医药有限公司 用于免疫治疗的嵌合抗原受体、制备方法及其应用
EP4086341A1 (de) * 2019-12-30 2022-11-09 Edigene Biotechnology Inc. Verfahren zur reinigung von ucart-zelle und deren verwendung
CN113088495A (zh) * 2020-01-09 2021-07-09 苏州方德门达新药开发有限公司 工程改造的t细胞、其制备及应用
US20220356252A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
WO2023227018A1 (zh) * 2022-05-25 2023-11-30 羿尊生物医药（浙江）有限公司 靶向细胞膜受体蛋白的融合蛋白及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product

Also Published As

Publication number Publication date
EP0403156B1 (de) 1997-09-10
GR3025644T3 (en) 1998-03-31
ES2109228T3 (es) 1998-01-16
DE69031410T2 (de) 1999-01-21
JPH03219896A (ja) 1991-09-27
DK0403156T3 (da) 1998-04-27
EP0403156A1 (de) 1990-12-19
DE69031410D1 (de) 1997-10-16
CA2018248A1 (en) 1990-12-07

Similar Documents

Publication Publication Date Title
DE69031410D1 (de) Monoklonale Antikörper gegen den humanen alpha/beta-T-Zellenrezeptor, ihre Herstellung und Verwendung
DE68918497T2 (de) Monoklonale Mäuseantikörper gegen HIV-IP24 und ihre Verwendung in Diagnostika.
DE240975T1 (de) Menschliches gamma-interferon-spezifisches rezeptorprotein, antikoerper gegen dieses protein, verfahren zur herstellung dieses proteins und dieses antikoerpers und dieses protein und diesen antikoerper enthaltende zusammensetzungen.
DE3852054D1 (de) Monoklonale Antikörper gegen Glycolipid-Antigene und ihre Verwendung.
DE68913402D1 (de) Antikörper mit hoher Affinität für Methamphetamine sowie geeignetes Immunogen für seine Herstellung.
DE3785967T2 (de) Monoklonale Antikörper gegen C5A und DES-ARG74-C5A, ihre Herstellung und ihre Verwendung.
DE3788148D1 (de) Monoklonale Antikörper und deren Verwendung.
DE69504959T2 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
ATA111789A (de) Humaner monoklonaler antikörper und hybridom zur herstellung desselben
DE3882727D1 (de) Mycoplasma-membran-antigene und ihre verwendung.
DE3682491D1 (de) Immobilisierter c-peptid-antikoerper, seine herstellung und verwendung.
DE3583296D1 (de) Oncofetal spezifische monoklonale antikoerper, deren herstellung und verwendung.
DE69130845T2 (de) HLA-DR Antigen-Gen, dessen Nukleotidsequenz und Verwendung
DE3888604T2 (de) Monoklonale Antikörper gegen Antithrombinbindende Substanz und seine Verwendungen.
DE58908815D1 (de) Monoklonaler Antikörper gegen Pseudomonas aeruginosa, seine Herstellung und Verwendung.
DE68926899T2 (de) Hybride monoklonale Antikörper, ihre Herstellung und Verwendung
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
DE3787239T2 (de) Komplementabhängiger zytolytischer monoklonaler Antikörper gegen Trichomonas vaginalis und seine therapeutische und diagnostische Verwendung.
DE69733051D1 (de) Monoklonaler antikörper gegen ratte beta-2-integrin alpha d untereinheit und entsprechendes hybridoma
DE3687542D1 (de) Monoklonaler antikoerper gegen humanes protein c.
ATE205255T1 (de) Spezifische antikörper gegen aktivierte plättchen,ihre herstellung und ihre verwendung in diagnose und therapie
ATE144286T1 (de) Monoklonale antikörper gegen den plasmin- antiplasmin komplex, verfahren zu ihrer herstellung sowie ihre verwendung
ATE89861T1 (de) Monoklonale antikoerper gegen c5a und des-arg74c5a, ihre herstellung und ihre verwendung.
DE69126302T2 (de) Monoklonaler antikörper gegen herzglykosid und dessen verwendung
ATE99332T1 (de) Monoklonale antikoerper gegen menschliche interleukin-4 und die sie erzeugenden hybridomen.

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 0403156

Country of ref document: EP

EELA Cancelled due to lapse of time